MX2023011848A - Tratamientos contra el prurigo nodular. - Google Patents

Tratamientos contra el prurigo nodular.

Info

Publication number
MX2023011848A
MX2023011848A MX2023011848A MX2023011848A MX2023011848A MX 2023011848 A MX2023011848 A MX 2023011848A MX 2023011848 A MX2023011848 A MX 2023011848A MX 2023011848 A MX2023011848 A MX 2023011848A MX 2023011848 A MX2023011848 A MX 2023011848A
Authority
MX
Mexico
Prior art keywords
treatments
prurigo nodularis
nemolizumab
antibody
prevention
Prior art date
Application number
MX2023011848A
Other languages
English (en)
Inventor
Francois Rousseau
Christophe Piketty
Valerie Julia
Jayendra Kumar Krishnaswamy
Original Assignee
Galderma Holding SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Holding SA filed Critical Galderma Holding SA
Publication of MX2023011848A publication Critical patent/MX2023011848A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Fats And Perfumes (AREA)

Abstract

En la presente se describen tratamientos y prevenciones para prurigo nodular (PN), anticuerpos y composiciones farmacéuticas para su uso en el tratamiento o la prevención de PN, y usos de un anticuerpo anti-IL-31RA (por ejemplo, nemolizumab) en la elaboración de un medicamento para el tratamiento o la prevención de PN. También se describen en la presente biomarcadores de PN y métodos para alterar o mejorar estos biomarcadores mediante tratamientos con un anticuerpo que se une a IL-31RA (por ejemplo, nemolizumab).
MX2023011848A 2021-04-07 2022-04-07 Tratamientos contra el prurigo nodular. MX2023011848A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163172020P 2021-04-07 2021-04-07
US202263323409P 2022-03-24 2022-03-24
PCT/IB2022/053250 WO2022215017A1 (en) 2021-04-07 2022-04-07 Treatments for prurigo nodularis

Publications (1)

Publication Number Publication Date
MX2023011848A true MX2023011848A (es) 2024-03-22

Family

ID=81580003

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011848A MX2023011848A (es) 2021-04-07 2022-04-07 Tratamientos contra el prurigo nodular.

Country Status (11)

Country Link
US (1) US20220411518A1 (es)
EP (1) EP4319807A1 (es)
JP (1) JP2024515578A (es)
KR (1) KR20240004471A (es)
AU (1) AU2022252984A1 (es)
BR (1) BR112023020621A2 (es)
CA (1) CA3214379A1 (es)
IL (1) IL307488A (es)
MX (1) MX2023011848A (es)
TW (1) TW202304510A (es)
WO (1) WO2022215017A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024047497A1 (en) * 2022-09-02 2024-03-07 Galderma Holding SA Treatments for prurigo nodularis
WO2024137664A1 (en) * 2022-12-22 2024-06-27 Regents Of The University Of Minnesota Methods for detecting glioblastoma in extracellular vesicles

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
WO2000075314A1 (fr) 1999-06-02 2000-12-14 Chugai Research Institute For Molecular Medicine, Inc. Proteine receptrice d'hemopoietine
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
BR112021008417A2 (pt) * 2018-11-02 2021-09-14 UNION therapeutics A/S Salicilanilidas halogenadas para tratar os sintomas de dermatite
US11236157B2 (en) * 2019-01-28 2022-02-01 Galderma Holding SA Treatment of skin lesions and pruritus in prurigo nodularis patients

Also Published As

Publication number Publication date
JP2024515578A (ja) 2024-04-10
AU2022252984A1 (en) 2023-11-23
BR112023020621A2 (pt) 2023-12-19
WO2022215017A1 (en) 2022-10-13
CA3214379A1 (en) 2022-10-13
TW202304510A (zh) 2023-02-01
IL307488A (en) 2023-12-01
EP4319807A1 (en) 2024-02-14
US20220411518A1 (en) 2022-12-29
KR20240004471A (ko) 2024-01-11

Similar Documents

Publication Publication Date Title
MX2023011848A (es) Tratamientos contra el prurigo nodular.
EA201792273A1 (ru) Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела
EA201992590A1 (ru) Стабильные композиции антител к рецептору программируемой гибели 1 (pd-1) и способы их применения
MX2020009862A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
BR112019023754A2 (pt) anticorpo anti-sirpalpha ou um fragmento de ligação ao antígeno do mesmo, composição farmacêutica, e, combinação do anticorpo anti-sirpalpha ou da composição farmacêutica.
BR112019005823A2 (pt) tratamento para enxaqueca refratária
BR112020016331A8 (pt) Métodos para tratar câncer com anticorpos anti-pd-1
JO3559B1 (ar) جسم مضاد لعلاج أو الوقاية من الصداع النصفي وطريقة استخدامه
EP4223774A3 (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
WO2019014328A3 (en) AGONISTIC ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF
MX2020007401A (es) Novedosa combinacion y uso de anticuerpos.
MX2019001814A (es) Tratamiento y remision virologica sostenida de infeccion de vih mediante anticuerpos a cd4 en pacientes estabilizados con haart.
EA201890578A1 (ru) Предотвращение, лечение и снижение (персистирующей) посттравматической головной боли
CL2019000585A1 (es) Combinación de un anticuerpo anti-cd20, inhibidor pi3 kinase-delta y anticuerdo anti-pd-1 o anti-pd-l1 para el tratamiento de cánceres hematológicos.
MX2022003005A (es) Composiciones y metodos de anticuerpos anti-cd39.
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
JOP20210166A1 (ar) علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r
MX2020009879A (es) Anticuerpos anti-il-27 y sus usos.
WO2022051591A3 (en) Nectin-4 antibodies and uses thereof
MX2021006980A (es) Anticuerpos anti-il-27 y usos de estos.
BR112021014854A2 (pt) Tratamento de lesões de pele e prurido em pacientes com prurigo nodularisis
BR112023000675A2 (pt) Terapia de combinação para tratamento de crescimento celular anormal
MX2023009681A (es) Composiciones de anticuerpos anti-tl1a y metodos de tratamiento en el pulmon.
MX2020009496A (es) Metodo para tratar asma o enfermedad alergica.
MX2022003719A (es) Anticuerpos anti-il-27 y sus usos.